New combo therapy for Hard-to-Treat gut tumors enters final testing phase
NCT ID NCT07185672
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether adding chemotherapy (capecitabine and temozolomide) to standard radiation therapy (PRRT) helps people with advanced neuroendocrine tumors of the stomach, pancreas, or intestines that show high activity on FDG PET scans. The study plans to enroll 162 adults whose tumors are well-differentiated but FDG-avid, meaning they are more aggressive. Participants will be randomly assigned to receive PRRT alone or PRRT plus chemotherapy, and researchers will compare how long they live without the cancer growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lutetium-177 PRRT (radiation therapy) plus capecitabine and temozolomide (chemotherapy)
- What this could lead to
- If successful, this combination could improve progression-free survival for people with aggressive neuroendocrine tumors that are not controlled by standard PRRT alone.
- What could go wrong
- This is a Phase 3 trial, but it is still recruiting and results are not yet available. Adding chemotherapy may increase side effects without guaranteeing better outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE GASTROENTEROPANCREATIC TUMOUR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
RECRUITINGNavi Mumbai, Maharashtra, 410210, India
-
Tata Memorial Hospital, Mumbai, India
RECRUITINGMumbai, Maharashtra, 400012, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.